The Intern At Work: Internal Medicine
220. Little Room for Relaxation- Heart Failure Preserved Ejection Fraction
Jan 14, 2024
This podcast discusses heart failure preserved ejection fraction (HFpEF), its diagnosis, comorbid conditions, and physical examination findings. It also explores the management options, challenges, and limited therapeutic recommendations for improving outcomes. Additionally, it highlights the results of two randomized trials studying the impact of SGL-II inhibitors on heart failure with preserved ejection fraction.
14:45
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- HFpEF is a prevalent type of heart failure characterized by diastolic dysfunction and normal ejection fraction.
- SGLT2 inhibitors, such as empagliflozin and dapagliflozin, have shown significant reductions in heart failure hospitalizations in patients with HFpEF.
Deep dives
Understanding Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a prevalent and growing global pandemic, characterized by diastolic dysfunction and normal ejection fraction. Risk factors for developing HFpEF include aging, hypertension, coronary artery disease, diabetes, obesity, and valvular heart disease. Symptoms of HFpEF include dyspnea on exertion, orthopnea, and paroxysmal nocturnal dyspnea, with fatigue being a common complaint. Diagnosis involves a thorough history, physical examination, chest x-ray, ECG, BNP level, and echocardiogram.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
